Toxicity of antiretroviral therapy and implications for drug development
- 1 August 2003
- journal article
- review article
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 2 (8) , 624-634
- https://doi.org/10.1038/nrd1151
Abstract
No abstract availableKeywords
This publication has 93 references indexed in Scilit:
- Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD studyAIDS, 2003
- Efavirenz-induced psychosis leading to involuntary detentionAIDS, 2003
- Therapeutic Drug MonitoringDrugs, 2003
- Increased risk of lipoatrophy under stavudine in HIV-1-infected patientsAIDS, 2002
- A single-nucleotide polymorphism in the sterol-regulatory element-binding protein 1c gene is predictive of HIV-related hyperlipoproteinaemiaAIDS, 2001
- Reactivation of Hepatitis B Virus Replication Accompanied by Acute Hepatitis in Patients Receiving Highly Active Antiretroviral TherapyClinical Infectious Diseases, 2001
- Metabolic Abnormalities and Cardiovascular Disease Risk Factors in Adults with Human Immunodeficiency Virus Infection and LipodystrophyClinical Infectious Diseases, 2001
- Risk Factors for Hepatotoxicity in HIV-1--Infected Patients Receiving Ritonavir and Saquinavir with or without StavudineClinical Infectious Diseases, 2000
- Long-term hydroxyurea in combination with didanosine and stavudine for the treatment of HIV-1 infectionAIDS, 2000
- Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistanceThe Lancet, 1998